Acute pulmonary hypertension in infants and children cGMP-related drugs

Pediatric Critical Care Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages

  Fraisse, Alain ^a   Wessel, David L ^b  

^a TIMONE HOSPITAL   (France)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Congenital heart disease; Inhaled nitric oxide; Postoperative pulmonary hypertension; Sildenafil

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; NESIRITIDE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ACUTE DISEASE; CHILD; CONFERENCE PAPER; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; ENZYME METABOLISM; ERYTHEMA; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; OPTIMAL DRUG DOSE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TACHYCARDIA; VASCULAR SMOOTH MUSCLE;

EID: 77949434310     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181c8e6e9     Document Type: Conference Paper

References (32)

1. Wessel DL, Adatia I, Giglia TM, et al: Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88:2128-2138
2. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117
3. Tantini B, Manes A, Fiumana E, et al: Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100:131-138
4. Gyurko R, Kuhlencordt P, Fishman MC, et al: Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J Physiol 2000; 278: H971-H981
5. Hirata K, Adji A, Vlachopoulos C, et al: Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96:436-440
6. Nagendran J, Archer SL, Soliman D, et al: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116:238-248
7. GaliéN, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 352: 2148-2157
8. Sastry BKS, Narasimhan C, Krishna Reddy N, et al: Clinical efficacy of sildenafil in primary pulmonary hypertension. A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153
9. Bharani A, Mathew V, Sahu A, et al: The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55:55-59
10. Singh TP, Rohit M, Grover A, et al: A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151:851.e1-5
11. Simonneau G, Rubin LJ, GaliéN, et al: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 2008; 149:521-530
12. Trachte AL, Lobato EB, Urdaneta F, et al: Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79:194-197
13. Atz AM, Wessel D: Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307-310
14. Humpl T, Reyes JT, Holtby H, et al: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Circulation 2005; 111:3274-3280
15. Namachivayam P, Theilen U, Butt WW, et al: Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174:1042-1047
16. Lee JE, Hillier SC, Knoderer CA: Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008; 23:329-1234
17. Baquero H, Soliz A, Neira F, et al: Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006; 117: 1077-1083
18. Forrester MB, Artalejo L: Pattern of sildenafil calls to Texas poison control centers, 1998 -2004. J Toxicol Environ Health A 2006; 69:497-503
19. Sivaswamy L, Vanstavern GP: Ischemic optic neuropathy in a child. Pediatr Neurol 2007; 37:371-372
20. Raja SG, Danton MD, MacArthur KJ, et al: Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth 2007; 21:203-207
21. Wills BK, Albinson C, Wahl M, et al: Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient. Clin Toxicol 2007; 45:798-800
22. Zusman RM, Morales A, Glasser DB, et al: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83:35C-44C
23. Schulze-Neick I, Hartenstein P, Li J, et al: Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108(Suppl II):II-167-II-173
24. Stocker C, Penny DJ, Brizard CP, et al: Intravenous sildenafil and inhaled nitric oxide: A randomised trial in infants after cardiac surgery. Intensive Care Med 2003; 29: 1996-2003
25. Fraisse A, Butrous G, Taylor MB, et al: Randomized controlled trial of IV sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Circulation 2007; 116:II-350-II-351
26. Ryhammer PK, Shekerdemian LS, Penny DJ, et al: Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res 2006; 59:762-766
27. Haase E, Bigam DL, Cravetchi O, et al: Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets. Shock 2006; 26:99-106
28. Bagdyman N, Fleck T, Bitterling B, et al: Influence of intravenous sildenafil on cerebral oxygenation measured by near-infrared spectroscopy in infants after cardiac surgery. Pediatr Res 2006; 59:462-465
29. Steinhorn RH, Kinsella JP, Pierce C, et al: Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155:841-847.e1
30. Tessler RB, Zadinello M, Fiori H, et al: Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. Pediatr Crit Care Med 2008; 9:330-332
31. Bernus A, Wagner BD, Accurso F, et al: Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135:745-751
32. Mahle WT, Cuadrado AR, Kirshbom PM, et al: Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005; 6:543-546